Author:
Pettengell R.,Schwenkglenks M.,Bosly A.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference6 articles.
1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453
2. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G; for the Lymphoma Dose Project: a National Study (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283
3. Marangolo M, Bengala C, Conte PF, Danova M, Pronzato P, Rosti G, Sagrada P (2006) Dose and outcome: the hurdle of neutropenia. Oncol Rep 16:233–248
4. Pettengell R, Bosly A, Bron D, Schwenkglenks M, Johnson P, Van Hoof A, Hancock B, De Brock R, Pagliuca A, Berneman Z, Thomas R, Ferrant A, Joyner M, Dauwe M, Verhoef G, Hoskin P (2006) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Haematologica/Hematol J 91:69 (Abs 0185)
5. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, The German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献